Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. ILB-H82W6) stimulates secretion of IL-17 by mousespleen cells. The ED50 for this effect is 0.191-0.2173 ng/mL (Routinely tested).
Cell based assay shows that the secretion of IL-17 induced by Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. ILB-H82W6) is inhibited by increasing concentration of the anti-human IL-23 neutralizing antibody. The IC50 is between 0.25-1.40 ng/mL (Routinely tested).
Captured Biotinylated Human IL-23A&IL-12B Heterodimer Protein, His,Avitag&Tag Free (Cat. No. ILB-H82W6) on Biotin CAP - Series S sensor Chip can bind Human IL-23 R, His Tag (Cat. No. ILR-H52H4) affinity constant of 4.77 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Captured Human IL-23 R, Fc Tag (Cat. No. ILR-H5254) on CM5 chip via anti-human IgG Fc antibodies surface can bind Human IL-23A&IL-12B Heterodimer Protein, His Tag&Tag Free (Cat. No. ILB-H52W5) with an affinity constant of 5.36 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Ustekinumab | CNTO-1275; C-340; AVT-04 | Approved | 喜达诺, Stelara | United States | Plaque psoriasis | Janssen Biotech Inc | 2009-09-25 | Multiple Sclerosis; Dermatitis, Atopic; Plaque psoriasis; Crohn Disease; Common Variable Immunodeficiency; Uveitis; Hidradenitis Suppurativa; Arthritis, Psoriatic; Colitis, Ulcerative; Lupus Erythematosus, Systemic; Takayasu Arteritis; Psoriasis; Liver Cirrhosis, Biliary; Arthritis, Juvenile; Ichthyosis; Sjogren's Syndrome; Pouchitis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Dermatomyositis; Non-radiographic axial spondyloarthritis; Polymyositis; Diabetes Mellitus, Type 1 | Details | |
Ustekinumab biosimilar(Amgen) | ABP-654 | Approved | Amgen Inc | Wezlana, WEZLANA | United States | Arthritis, Psoriatic; Plaque psoriasis; Colitis, Ulcerative; Crohn Disease | Amgen Inc | 2023-10-31 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
Ustekinumab | CNTO-1275; C-340; AVT-04 | Approved | 喜达诺, Stelara | United States | Plaque psoriasis | Janssen Biotech Inc | 2009-09-25 | Multiple Sclerosis; Dermatitis, Atopic; Plaque psoriasis; Crohn Disease; Common Variable Immunodeficiency; Uveitis; Hidradenitis Suppurativa; Arthritis, Psoriatic; Colitis, Ulcerative; Lupus Erythematosus, Systemic; Takayasu Arteritis; Psoriasis; Liver Cirrhosis, Biliary; Arthritis, Juvenile; Ichthyosis; Sjogren's Syndrome; Pouchitis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Dermatomyositis; Non-radiographic axial spondyloarthritis; Polymyositis; Diabetes Mellitus, Type 1 | Details | |
Ustekinumab biosimilar(Amgen) | ABP-654 | Approved | Amgen Inc | Wezlana, WEZLANA | United States | Arthritis, Psoriatic; Plaque psoriasis; Colitis, Ulcerative; Crohn Disease | Amgen Inc | 2023-10-31 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
anti-cancer mRNA therapeutics (Moderna Therapeutics) | mRNA-2752 | Phase 1 Clinical | Moderna Inc, Astrazeneca Plc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Lymphoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Ustekinumab Biosimilar(Celltrion) | CT-P43 | Phase 3 Clinical | Celltrion Inc | Psoriasis | Details |
SOR-102 | SOR-102 | Phase 1 Clinical | Sorriso Pharmaceuticals Inc | Inflammatory Bowel Diseases; Colitis, Ulcerative | Details |
LY-900021 | LY-900021 | Phase 1 Clinical | Halozyme Therapeutics Inc, Eli Lilly And Company | Details | |
IL-23/CGRP bispecific antibody (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Autoimmune Diseases | Details | |
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Autoimmune Diseases | Details | |
Ustekinumab biosimilar (BioFactura) | BFI-751 | Phase 1 Clinical | BioFactura Australia Pty Ltd | Psoriasis | Details |
Ustekinumab Biosimilar (qyuns) | QX-001-S; HDM-3001; QX-001S | Phase 3 Clinical | Qyuns Therapeutics Co Ltd | Psoriasis; Plaque psoriasis | Details |
Brazikumab | AMG-139; MEDI-2070; Anti-IL-23-MAb (Amgen) | Phase 2 Clinical | Amgen Inc | Inflammatory Bowel Diseases; Psoriasis; Colitis, Ulcerative; Crohn Disease | Details |
Ustekinumab biosimilar(CSPC Pharma) | SYSA-1902 | Phase 3 Clinical | Jushi Biopharmaceutical Co Ltd | Psoriasis; Plaque psoriasis | Details |
Ustekinumab biosimilar(Formycon) | FYB-202 | Phase 3 Clinical | Formycon | Psoriasis | Details |
Kagocel | Clinical | Nearmedic Plus Llc | Respiratory Tract Infections; Respirovirus Infections; Influenza, Human | Details | |
Ustekinumab biosimilar(Rani Therapeutics) | RT-111 | Phase 1 Clinical | Rani Therapeutics Llc | Psoriasis | Details |
anti-cancer mRNA therapeutics (Moderna Therapeutics) | mRNA-2752 | Phase 1 Clinical | Moderna Inc, Astrazeneca Plc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Lymphoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Ustekinumab Biosimilar(Celltrion) | CT-P43 | Phase 3 Clinical | Celltrion Inc | Psoriasis | Details |
SOR-102 | SOR-102 | Phase 1 Clinical | Sorriso Pharmaceuticals Inc | Inflammatory Bowel Diseases; Colitis, Ulcerative | Details |
LY-900021 | LY-900021 | Phase 1 Clinical | Halozyme Therapeutics Inc, Eli Lilly And Company | Details | |
IL-23/CGRP bispecific antibody (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Autoimmune Diseases | Details | |
Ustekinumab Biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Autoimmune Diseases | Details | |
Ustekinumab biosimilar (BioFactura) | BFI-751 | Phase 1 Clinical | BioFactura Australia Pty Ltd | Psoriasis | Details |
Ustekinumab Biosimilar (qyuns) | QX-001-S; HDM-3001; QX-001S | Phase 3 Clinical | Qyuns Therapeutics Co Ltd | Psoriasis; Plaque psoriasis | Details |
Brazikumab | AMG-139; MEDI-2070; Anti-IL-23-MAb (Amgen) | Phase 2 Clinical | Amgen Inc | Inflammatory Bowel Diseases; Psoriasis; Colitis, Ulcerative; Crohn Disease | Details |
Ustekinumab biosimilar(CSPC Pharma) | SYSA-1902 | Phase 3 Clinical | Jushi Biopharmaceutical Co Ltd | Psoriasis; Plaque psoriasis | Details |
Ustekinumab biosimilar(Formycon) | FYB-202 | Phase 3 Clinical | Formycon | Psoriasis | Details |
Kagocel | Clinical | Nearmedic Plus Llc | Respiratory Tract Infections; Respirovirus Infections; Influenza, Human | Details | |
Ustekinumab biosimilar(Rani Therapeutics) | RT-111 | Phase 1 Clinical | Rani Therapeutics Llc | Psoriasis | Details |
This web search service is supported by Google Inc.